Spinal Muscular Atrophy (SMA) Awareness Month – Research Spotlight

Spinal Muscular Atrophy (SMA) Awareness Month – Research Spotlight

Affecting approximately 1 in 10,000 live births, Spinal Muscular Atrophy (SMA) is a rare neuromuscular disorder characterized by the loss of motor neurons and progressive muscle wasting, making it the leading genetic cause of infant mortality worldwide.
August is Spinal Muscular Atrophy (SMA) Awareness Month, and we are thrilled to feature high-impact research led by members of the NMD4C community!
Published recently in Annals of Neurology, a study titled “Maternal-Fetal Administration of Risdiplam Partially Rescues the SMNΔ7 Mouse Model of Spinal Muscular Atrophy” explores the potential of early prenatal therapeutic interventions for SMA.

Key Findings:

Maternal-Fetal Administration of Risdiplam Partially Rescues the SMNΔ7 Mouse Model of Spinal Muscular Atrophy

 

 

  • Prenatal administration of a risdiplam-like compound was safe for pregnant female mice.
  • The progeny demonstrated increased survival, motor function, weight gain, and preserved muscle fiber area.
  • Results suggest that combining early prenatal intervention with postnatal therapy may offer optimal outcomes for SMA.

 

Maternal-Fetal Administration of Risdiplam Partially Rescues the SMNΔ7 Mouse Model of Spinal Muscular AtrophyA huge congratulations to Lead author Dr. Emma Sutton, and co-author Rebecca Yaworski (members of the NMD4C Basic Science Trainee Committee, BSTC), as well as our Investigators Drs. Rashmi Kothary and Hugh McMillan, and Ariane Beauvais on this work from the Ottawa Hospital Research Institute and CHEO!

This work was also made possible with the support of NMD4C, Cure SMA, Muscular Dystrophy Canada and CIHR Institute of Musculoskeletal Health and Arthritis (IMHA)

 

Download the full publication

Watch the Video Abstract

Spinal Muscular Atrophy (SMA) Awareness Month – Research Spotlight

Read next...

CPNG 2026

Zolgensma® Safety Update and CPNG Guidance for Families

The Canadian Pediatric Neuromuscular Group (CPNG) has issued a statement for families regarding recent reports of tumours in children treated with Zolgensma® (onasemnogene abeparvovec) gene therapy for spinal muscular atrophy (SMA). The statement outlines current evidence, considerations for follow-up care, and information for families and healthcare providers.

2026 Trainee Publication of the Year Awardee Spotlight on Jules Granet

Could You Be Our Next Awardee? Meet Jules Granet, NMD4C’s 2026 Publication of the Year Awardee

Nominations are open till by 18 January 2027!
In 2026, Jules Granet, a PhD Candidate at McGill University and trainee in Dr. Natasha Chang’s laboratory received an NMD4C Publication of the Year Award for research investigating how muscle stem cell dysfunction contributes to impaired muscle regeneration in Duchenne muscular dystrophy. Nominate yourself or a neuromuscular colleague whose research, clinical care, leadership, advocacy, or community contributions deserve to be recognized.

Save the date: 8th Ottawa International Conference On Neuromuscular Disease & Biology

Early Bird Registration Now Open: 8th Ottawa International Conference On Neuromuscular Disease & Biology

We are happy to announce that early bird registration is now open for the 8th Ottawa International Conference On Neuromuscular Disease & Biology which will be held on October 14-16, 2027 at the Fairmont Château Laurier in Ottawa, Canada. Now under the leadership of NMD4C Investigators; Dr. Mireille Khacho, Dr. Hanns Lochmuller, Dr. Bernard Jasmin, and Dr. Rashmi Kothary.